News
-
-
PRESS RELEASE
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Enrollment in Jaguar Health's placebo-controlled Phase 2 study for microvillus inclusion disease (MVID) reaches 25%. Crofelemer shows promise in reducing total parenteral nutrition in pediatric patients with MVID and short bowel syndrome, seeking business partnerships for non-dilutive funding -
-
PRESS RELEASE
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present virtually at Emerging Growth Conference on June 18, 2025. Focus on pharmaceuticals from rainforest plants for gastrointestinal distress. Notable brands: Mytesi, Napo Therapeutics -
-
PRESS RELEASE
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jaguar Health, Inc. announces goals to expand crofelemer usage from chemotherapy-induced to general diarrhea treatment in dogs. Research studies and partnerships in progress -
-
PRESS RELEASE
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health, Inc. to discuss Phase 3 OnTarget trial results for metastatic breast cancer subgroup. Focus on orphan population and expanded access program. Virtual fireside chat with CEO Lisa Conte on June 10, 2025 -
-
PRESS RELEASE
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Jaguar Health's Napo Pharmaceuticals shares plans to seek approval for crofelemer in cancer therapy-related diarrhea for metastatic breast cancer patients. Key discussions with FDA highlighted in Type C Meeting
